Sermorelin: Complete Research Guide & Chemical Profile

Sermorelin (sermorelin acetate, also known as GRF 1-29 NH2) is a synthetic peptide analog corresponding to the first 29 amino acids of the 44-amino-acid endogenous human growth hormone-releasing hormone (GHRH). This truncated fragment retains full biological activity at the GHRH receptor (GHRH-R), as the first 29 residues contain all structural determinants necessary for receptor binding and activation. Sermorelin stimulates pulsatile growth hormone (GH) release from anterior pituitary somatotrophs through selective GHRH-R agonism.

• Generic Name: Sermorelin acetate
• INN: Sermorelin
• CAS Registry Number: 86168-78-7
• Molecular Formula: C149H246N44O42S
• Molecular Weight: ~3357.93 Da
• Amino Acid Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
• Peptide Length: 29 amino acid residues
• C-Terminal Modification: Amidated (-NH2)
• Classification: Synthetic GHRH analog, GHRH receptor agonist

Sermorelin is a linear 29-residue peptide with the sequence H-Tyr1-Ala2-Asp3-Ala4-Ile5-Phe6-Thr7-Asn8-Ser9-Tyr10-Arg11-Lys12-Val13-Leu14-Gly15-Gln16-Leu17-Ser18-Ala19-Arg20-Lys21-Leu22-Leu23-Gln24-Asp25-Ile26-Met27-Ser28-Arg29-NH2. The C-terminus is amidated for enhanced metabolic stability and receptor binding affinity. Structure-activity relationship studies have established that the N-terminal residues (positions 1-6) are critical for receptor binding, while the central and C-terminal segments contribute to alpha-helical conformation and receptor activation efficiency.

The peptide adopts an amphipathic alpha-helical conformation in solution and upon receptor binding. The tyrosine at position 1 is essential for biological activity, and modifications at this position result in substantial loss of potency. The methionine at position 27 represents a metabolic vulnerability, as oxidation to methionine sulfoxide reduces biological activity. The amidated C-terminus is critical, as the free acid form shows markedly reduced receptor binding.

Sermorelin activates the GHRH receptor (GHRH-R, also designated GRF-R), a 423-amino-acid class B G protein-coupled receptor (GPCR) expressed primarily on anterior pituitary somatotrophs. Upon binding, sermorelin induces conformational changes in GHRH-R that activate the stimulatory G protein (Gs), leading to adenylyl cyclase activation, intracellular cAMP elevation, and protein kinase A (PKA) activation. This signaling cascade triggers both rapid GH vesicle exocytosis and longer-term GH gene transcription.

A critical feature of sermorelin-induced GH release is its pulsatile nature. Unlike exogenous GH administration, which produces non-physiological sustained GH elevation, sermorelin preserves the endogenous hypothalamic-pituitary feedback mechanisms. Somatostatin continues to regulate GH pulse amplitude and frequency, and IGF-1-mediated negative feedback remains intact. This physiological mode of action results in GH secretion patterns that more closely resemble normal endocrine physiology.

Sermorelin is rapidly absorbed after subcutaneous administration and exhibits a short plasma half-life due to enzymatic degradation. Pharmacokinetic studies by Wilton et al. (1993) characterized the absorption and elimination profile after both intravenous and intranasal administration in healthy subjects.

• Route of administration: subcutaneous injection (primary), intravenous (research), intranasal (investigational)
• Plasma half-life: approximately 10-20 minutes after intravenous administration
• Onset of GH release: within 15-30 minutes after subcutaneous injection
• Peak GH response: typically 30-60 minutes post-administration
• Duration of GH elevation: approximately 2-3 hours
• Intranasal bioavailability: 3-5% relative to intravenous (Wilton et al., 1993)
• Metabolic clearance: primarily enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and other serum proteases
• Primary cleavage site: between Ala2 and Asp3 (DPP-IV mediated)

Sermorelin serves as a fundamental research tool across multiple domains of endocrine and neuroendocrine investigation. Its well-characterized receptor pharmacology and predictable GH-releasing activity make it a standard reference compound for GHRH-R studies.

• Diagnostic endocrinology: GH reserve testing, differentiation of hypothalamic vs. pituitary GH deficiency
• Somatotroph biology: GHRH-R signaling pathway characterization, cAMP response studies, GH gene regulation
• Aging research: age-related decline in GH secretion (somatopause), neuroendocrine axis assessment
• Anti-doping analytical chemistry: development of detection methods for GHRH analogs in biological matrices (Ucakturk et al., 2025)
• Oncology: GHRH-R expression in extrapituitary tissues, role of GHRH signaling in tumor biology
• Combination studies: synergistic GH release when combined with GHRP/ghrelin mimetics, somatostatin withdrawal paradigms

Sermorelin acetate was approved by the US FDA under the brand name Geref (Serono Laboratories) for two indications: as a diagnostic agent for evaluating pituitary GH secretory capacity (Geref Diagnostic, approved 1997) and for the treatment of idiopathic GH deficiency in children with growth failure (Geref, approved earlier). The diagnostic application utilized sermorelin as a GHRH stimulation test to differentiate hypothalamic from pituitary causes of GH deficiency.

The therapeutic formulation (Geref) was voluntarily withdrawn from the US market by EMD Serono in 2008 for commercial reasons, not due to safety concerns. The diagnostic formulation was also discontinued. Despite market withdrawal, sermorelin remains a well-characterized reference compound in endocrine research and its pharmacological profile is extensively documented in the scientific literature.

Several GHRH analogs have been developed with modifications aimed at improving metabolic stability, receptor affinity, or duration of action compared to the native GHRH(1-44) or sermorelin.

• Sermorelin (GHRH 1-29 NH2): 29 residues, short half-life (~10-20 min), full GHRH-R agonist, well-characterized safety profile, FDA-approved history
• Tesamorelin (GHRH 1-44 with trans-3-hexenoic acid): full-length 44 residues with N-terminal modification, improved stability, FDA-approved for HIV-associated lipodystrophy
• CJC-1295 (modified GRF 1-29): 29 residues with 4 amino acid substitutions (Ala2→D-Ala, Asn8→Gln, Ala15→Ala, Met27→Leu) for DPP-IV resistance; available with or without Drug Affinity Complex (DAC) for albumin binding
• CJC-1293: GHRH analog intermediate between sermorelin and CJC-1295; detected alongside sermorelin in anti-doping assays
• GHRH(1-44)NH2: native full-length hormone; identical first 29 residues to sermorelin; additional C-terminal residues contribute minimally to receptor binding

• Lyophilized powder: store at -20°C; protect from light and moisture; stable for 24+ months
• Reconstitution: dissolve in sterile bacteriostatic water, 0.9% sodium chloride, or PBS
• Reconstituted solution: store at 2-8°C; use within 14 days for bacteriostatic water preparations
• Methionine oxidation: avoid exposure to oxidizing agents; Met27 is susceptible to oxidation which reduces bioactivity
• pH sensitivity: optimal stability at pH 4.0-5.0; degradation accelerates at neutral and alkaline pH
• Avoid repeated freeze-thaw cycles; prepare single-use aliquots for long-term storage at -20°C to -80°C

• RP-HPLC: primary purity assessment; >98% purity for pharmaceutical grade; characteristic retention time profile
• Mass spectrometry: ESI-MS or MALDI-TOF for molecular weight confirmation (expected ~3357.93 Da for free base)
• Amino acid analysis: quantitative composition verification of all 29 residues
• Peptide content: typically 75-85% by weight (adjusted for acetate, water, and counterion content)
• Endotoxin: <0.1 EU/mg by LAL method for injectable preparations
• Nano-LC-Q/Orbitrap MS: high-sensitivity detection method developed for anti-doping screening (LOD ≤0.5 ng/mL)

Sermorelin continues to serve as an important reference standard and research tool in endocrine pharmacology. Current research directions include investigation of GHRH-R signaling in extrapituitary tissues, development of GHRH-R antagonists (MIA class) for oncology applications, and refinement of analytical detection methods for anti-doping purposes. The established safety database from its period of clinical use provides a valuable foundation for comparative evaluation of newer GHRH analogs.

Emerging research by Schally and colleagues has explored GHRH-R antagonists derived from the sermorelin scaffold, demonstrating that GHRH pathway modulation extends well beyond pituitary GH regulation to include anti-inflammatory and anti-proliferative effects in cancer and inflammatory disease models. These findings suggest that GHRH-R pharmacology represents a broader therapeutic target than originally appreciated.

• Read more: TRH (Thyrotropin-Releasing Hormone): Research Guide & Chemical Profile → https://www.chemverify.com/learn/trh-thyrotropin-releasing-hormone-research-guide
• Read more: Ipamorelin + CJC-1295 (No DAC) Stack: Synergy Research Guide → https://www.chemverify.com/learn/ipamorelin-cjc-1295-no-dac-stack-synergy
• Read more: TP508 (Chrysalin): Research Guide & Chemical Profile → https://www.chemverify.com/learn/tp508-chrysalin-research-guide-chemical-profile
• Read more: Semax for Cognitive Research: ACTH(4-10) Analog Mechanism → https://www.chemverify.com/learn/semax-cognitive-research-acth-mechanism